Viewing upper gastrointestinal cancers in a new light

January 05, 2021

Researchers from Tokyo Medical and Dental University (TMDU) describe an endoscopic modality for detecting upper gastrointestinal tract neoplasms by Linked Color Imaging that innovatively mixes light of different wavelengths to better depict mucosal changes

Tokyo, Japan - Recently there have been significant advances on several fronts in the ongoing war against cancer of the alimentary tract. Now, Japanese researchers report the development of another weapon: Linked Color Imaging (LCI), a novel endoscopic technique that improves detection of cancer by viewing the upper digestive tract mucosa under illumination that combines specific wavelengths of light to intensify subtle color variations indicative of neoplastic change.

Upper gastrointestinal (GI) endoscopy is routinely performed to detect tumorous changes or neoplasia in the pharynx, esophagus, and stomach and is conventionally done under White Light Imaging (WLI). Using the innovative LASEREO system developed by the Fujifilm Corporation, LCI technology balances white light with narrow-band short wavelength light in a specific ratio that deepens and enhances the contrast of red and white hues, thus intensifying nuances of mucosal transformation.

Though earlier studies have described the role of LCI in histological diagnosis of upper GI tract tumors, the research team felt the need for a large-scale, broad-based comparative study to assess its efficacy in neoplasm detection. "Our research was conducted in 19 hospitals across Japan involving 1502 patients with known past or current gastrointestinal cancer, representing a high-risk population" explains Dr Shoko Ono, lead author. "Patients underwent upper GI endoscopy under both WLI and LCI protocols wherein they were grouped according to which modality was performed first. Ingeniously, our study design ensured diagnostic accuracy; not only did each modality serve as a backup and crosscheck on the other, this was further followed by histopathological confirmation."

Dr Kenro Kawada, co-lead author, describes the results. "With LCI, lesions were detected in 8% of the patients but the detection rate was only 4.8% with WLI. Conversely, with WLI 3.5% of patients had a lesion overlooked but this rate was only 0.67% with LCI. This shows a clear superiority of LCI over conventionally illuminated endoscopic screening for discerning mucosal changes related to upper GIT neoplasia as it detected neoplasia 1.67 times more frequently."

Professor Mototsugu Kato, senior and corresponding author, explains the implications of their research. "Combined with previous studies that show the efficacy of LCI in detecting large intestinal neoplasia, our findings make a strong case for wider adoption of this modality in surveillance of the entire endoscopically accessible digestive tract. However, we need further research to confirm its efficacy in the hands of general clinicians for upper GI screening of an average population."
-end-
The article, "Linked Color Imaging Focused on Imaging for Neoplasm Detection in Upper Gastrointestinal Tract (LCI-FIND): a randomized trial" was published in Annals of Internal Medicine. at DOI: 10.7326/M19-2561

Tokyo Medical and Dental University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.